D
Daniela Sia
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 59
Citations - 6182
Daniela Sia is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Hepatocellular carcinoma & Cancer research. The author has an hindex of 21, co-authored 44 publications receiving 3656 citations. Previous affiliations of Daniela Sia include National Institutes of Health & University of Barcelona.
Papers
More filters
Journal ArticleDOI
Molecular therapies and precision medicine for hepatocellular carcinoma
TL;DR: Treatment advances have been made in the past few years, and further advancements are expected in the near future, including biomarker-driven treatments and immunotherapies, as discussed in this Review.
Journal ArticleDOI
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia,Augusto Villanueva,Scott L. Friedman,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet +5 more
TL;DR: Proposals of the cell of origin of liver tumorigenesis are reviewed and the classes of liver cancer based on molecular features are clarified and how they affect patient prognosis are clarified.
Journal ArticleDOI
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia,Yang Jiao,Iris Martinez-Quetglas,Olga Kuchuk,Olga Kuchuk,Carlos Villacorta-Martin,Manuel Castro de Moura,Juan Putra,Genis Camprecios,Laia Bassaganyas,Nicholas K. Akers,Bojan Losic,Samuel Waxman,Swan N. Thung,Vincenzo Mazzaferro,Manel Esteller,Manel Esteller,Manel Esteller,Scott L. Friedman,Myron Schwartz,Augusto Villanueva,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet +23 more
TL;DR: The findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Journal ArticleDOI
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta,Erin Bresnahan,Pedro Molina-Sánchez,Katherine E. Lindblad,Barbara Maier,Daniela Sia,Marc Puigvehí,Marc Puigvehí,Veronica Miguela,Maria Casanova-Acebes,Maxime Dhainaut,Carlos Villacorta-Martin,Aatur D. Singhi,Akshata Moghe,Johann von Felden,Johann von Felden,Lauren Tal Grinspan,Shuang Wang,Alice O. Kamphorst,Satdarshan P.S. Monga,Brian D. Brown,Augusto Villanueva,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Miriam Merad,Amaia Lujambio +26 more
TL;DR: A novel genetically-engineered mouse model of HCC enables interrogating how different genetic alterations affect immune surveillance and response to immunotherapies and shows that β-catenin activation promotes immune escape and resistance to anti-PD-1 and could represent a novel biomarker for HCC patient exclusion.
Journal ArticleDOI
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Supriya K. Saha,Christine A. Parachoniak,Krishna S. Ghanta,Julien Fitamant,Kenneth N. Ross,Mortada S. Najem,Sushma Gurumurthy,Esra A. Akbay,Daniela Sia,Daniela Sia,Helena Cornella,Oriana Miltiadous,Chad Walesky,Vikram Deshpande,Andrew X. Zhu,Aram F. Hezel,Katharine E. Yen,Kimberly Straley,Jeremy Travins,Janeta Popovici-Muller,Camelia Gliser,Cristina R. Ferrone,Udayan Apte,Josep M. Llovet,Kwok-Kin Wong,Sridhar Ramaswamy,Sridhar Ramaswamy,Nabeel Bardeesy +27 more
TL;DR: It is shown that mutant IDH blocks liver progenitor cells from undergoing hepatocyte differentiation through the production of 2HG and suppression of HNF-4α, a master regulator of hepatocyte identity and quiescence, and presents a novel genetically engineered mouse model of IDH-driven malignancy.